Ivermectin has a dual pharmacokinetic profile that differs significantly between topical and oral formulations. Topical ivermectin is designed for localized skin delivery with minimal systemic absorption, concentrating within the epidermis and pilosebaceous unit where Demodex mites reside. This limited penetration supports a strong safety profile and reduces the risk of systemic exposure while maintaining therapeutic activity in rosacea.
Oral ivermectin follows a systemic PK pattern characterized by good gastrointestinal absorption, extensive distribution into tissues, and a long elimination half‑life that supports single‑dose or intermittent dosing. Its lipophilicity and protein binding influence distribution, while hepatic metabolism and biliary excretion determine clearance. Understanding these PK differences is essential for interpreting ivermectin’s mechanism of action, clinical efficacy, and safety across dermatologic and parasitic indications. Explore related resources: Ivermectin MOA, Ivermectin oral vs topical, Ivermectin topical.
Ivermectin demonstrates a pharmacokinetic profile defined by high lipophilicity, slow tissue distribution, and a long elimination half‑life. These characteristics explain its sustained antiparasitic and anti‑inflammatory activity, as well as its excellent safety when used topically. The PK behavior differs significantly between oral and topical forms, but several core principles remain consistent across formulations.
Ivermectin is a highly lipophilic molecule, allowing it to accumulate within lipid‑rich tissues such as the epidermis and pilosebaceous units. This property enhances its ability to reach Demodex mites and maintain prolonged local activity.
Due to its lipophilicity and strong tissue binding, ivermectin distributes slowly throughout biological compartments. In systemic use, this results in extended tissue residence; in topical use, it supports long‑lasting epidermal concentrations.
Oral ivermectin has a long elimination half‑life (typically 12–36 hours), reflecting slow redistribution and clearance. While topical ivermectin does not produce measurable systemic levels, its prolonged retention in the skin mirrors this slow‑release behavior.
Topical ivermectin exhibits negligible systemic absorption. Plasma concentrations remain far below pharmacologically active levels, ensuring excellent safety and eliminating the risk of systemic toxicity.
| PK parameter | Ivermectin |
|---|---|
| Lipophilicity | High — accumulates in lipid‑rich tissues |
| Distribution | Slow — prolonged tissue residence |
| Half‑life | Long (12–36 h for oral; prolonged skin retention topically) |
| Topical absorption | Minimal — negligible systemic exposure |
The absorption profile of ivermectin differs dramatically between oral and topical formulations. These differences determine systemic exposure, safety, and clinical applicability. Oral ivermectin produces measurable plasma concentrations and systemic pharmacologic activity, while topical ivermectin remains almost entirely confined to the epidermis, resulting in negligible systemic absorption and excellent tolerability.
Oral ivermectin demonstrates 60–80% bioavailability, although absorption varies depending on gastrointestinal conditions and dietary fat content. Key PK characteristics include:
This systemic absorption is essential for treating nematode infections but irrelevant — and unnecessary — for dermatologic use.
Topical ivermectin behaves entirely differently. Its systemic absorption is less than 1%, and plasma concentrations remain far below pharmacologically active thresholds. Key features include:
This minimal absorption explains why topical ivermectin is safe for long‑term rosacea therapy and does not share the systemic risks of oral formulations.
| Parameter | Oral ivermectin | Topical ivermectin |
|---|---|---|
| Bioavailability | 60–80% | <1% |
| Effect of fatty food | Significant ↑ absorption | None |
| Tmax | 3–5 hours | Not clinically relevant |
| Plasma levels | High | Negligible |
Ivermectin’s distribution profile is defined by its high lipophilicity, extensive protein binding, and selective penetration into peripheral tissues. These properties influence both systemic pharmacology (oral use) and local dermatologic activity (topical use). Understanding ivermectin’s distribution helps explain its long half‑life, sustained antiparasitic effect, and excellent safety margin.
Ivermectin is strongly lipophilic, allowing it to accumulate in adipose tissue, sebaceous glands, and lipid‑rich compartments. This contributes to:
Ivermectin binds to plasma proteins at levels exceeding 90%. This high binding:
Topical ivermectin penetrates efficiently into the epidermis and pilosebaceous units, where Demodex mites reside. This targeted distribution is essential for its dermatologic efficacy and explains why topical concentrations are far higher in the skin than those achieved through oral dosing.
At standard therapeutic doses, ivermectin does not cross the blood–brain barrier due to active efflux by P‑glycoprotein transporters. This prevents interaction with mammalian GABA receptors and contributes to ivermectin’s excellent neurological safety profile.
| Distribution parameter | Description |
|---|---|
| Lipophilicity | High — accumulates in fat‑rich tissues |
| Protein binding | >90% bound to plasma proteins |
| Skin penetration | Strong — concentrates in epidermis and follicles |
| CNS penetration | None at therapeutic doses |
Ivermectin undergoes extensive hepatic metabolism, with the liver serving as the primary site of biotransformation. The metabolic profile differs significantly between oral and topical formulations, largely due to differences in systemic exposure. Oral ivermectin reaches high plasma concentrations and undergoes active enzymatic processing, while topical ivermectin remains mostly within the epidermis and therefore produces only trace systemic metabolites.
After oral administration, ivermectin is metabolized in the liver through oxidative pathways. The drug undergoes:
These reactions convert ivermectin into multiple metabolites, most of which are pharmacologically inactive.
The primary enzyme responsible for ivermectin metabolism is CYP3A4. Minor contributions from CYP2D6 and CYP2E1 have been reported, but CYP3A4 dominates the metabolic pathway. This explains potential interactions with strong CYP3A4 inhibitors when ivermectin is taken orally.
The metabolites produced during hepatic processing lack antiparasitic activity. Their formation facilitates biliary excretion and reduces systemic pharmacologic effects.
Topical ivermectin produces minimal systemic absorption, meaning hepatic metabolism is negligible. Most of the drug remains in the skin and is slowly degraded locally. In contrast, oral ivermectin undergoes full hepatic metabolism due to high systemic exposure.
| Metabolic pathway | Description |
|---|---|
| Primary enzyme | CYP3A4‑mediated oxidation |
| Metabolite activity | Mostly inactive |
| Oral metabolism | Extensive hepatic processing |
| Topical metabolism | Minimal due to low systemic absorption |
The elimination of ivermectin depends strongly on the route of administration. Oral ivermectin undergoes systemic distribution and hepatic metabolism before being excreted primarily via the biliary route. Topical ivermectin, however, produces negligible systemic exposure, meaning classical elimination pathways are not clinically relevant.
Oral ivermectin has a long and variable elimination half‑life, typically 12–36 hours. This prolonged half‑life reflects:
The majority of ivermectin and its metabolites are excreted through the biliary system into the feces. This pathway accounts for more than 90% of total elimination.
Only a small fraction of ivermectin (<2%) is excreted unchanged in the urine. Renal impairment does not significantly affect ivermectin clearance.
Because topical ivermectin remains localized in the skin and systemic absorption is below 1%, classical elimination pathways (biliary or renal) are not clinically meaningful. The drug is primarily degraded locally within the epidermis.
| Elimination parameter | Description |
|---|---|
| Half‑life | 12–36 hours (oral) |
| Primary excretion | Biliary → fecal elimination |
| Renal excretion | <2% unchanged |
| Topical elimination | No significant systemic clearance |
The pharmacokinetic behavior of topical and oral ivermectin differs so dramatically that they function almost as two separate therapeutic classes. These differences determine systemic exposure, safety, tissue distribution, and ultimately the clinical indications for each formulation. A detailed comparison is available at Ivermectin oral vs topical.
Topical ivermectin is engineered for localized epidermal activity. Its PK profile is defined by:
This PK pattern makes topical ivermectin ideal for rosacea and Demodex‑associated dermatoses, where high local concentrations and low systemic exposure are essential.
Oral ivermectin behaves entirely differently. Its PK profile includes:
These systemic PK characteristics are essential for treating helminth infections but unnecessary for dermatologic use.
| PK parameter | Topical ivermectin | Oral ivermectin |
|---|---|---|
| Absorption | <1% (negligible) | 60–80% (high) |
| Distribution | Localized to epidermis & follicles | Systemic, lipid‑rich tissues |
| Half‑life | Not systemically relevant | 12–36 hours |
| Clinical effect | Anti‑Demodex + anti‑inflammatory | Systemic antiparasitic |
The pharmacokinetic properties of ivermectin directly shape its mechanism of action (MOA). High lipophilicity, prolonged epidermal retention, and minimal systemic absorption create an ideal environment for targeted anti‑Demodex and anti‑inflammatory activity. A detailed mechanistic overview is available at Ivermectin MOA.
Ivermectin’s strong lipophilicity allows it to accumulate in sebaceous follicles, the natural habitat of Demodex folliculorum. This PK characteristic ensures:
Ivermectin remains in the epidermis for extended periods, supporting continuous suppression of:
This sustained presence explains the long‑lasting reduction of erythema and papulopustular activity.
Because systemic absorption is <1%, ivermectin avoids GABA‑related neurotoxicity and systemic pharmacologic effects. This PK feature is the foundation of its excellent tolerability in rosacea patients.
| PK factor | MOA impact |
|---|---|
| Lipophilicity | Follicular penetration → anti‑Demodex action |
| Skin retention | Sustained anti‑inflammatory effect |
| Systemic absorption | Minimal → high safety, no systemic toxicity |
| Local concentration | High → rapid clinical improvement |
The pharmacokinetics of topical ivermectin 1% in rosacea are defined by highly localized epidermal distribution, negligible systemic absorption, and prolonged retention in lipid‑rich structures. These PK characteristics directly support ivermectin’s clinical performance in papulopustular and Demodex‑associated rosacea. A detailed clinical overview is available at Ivermectin for rosacea.
Ivermectin concentrates in the stratum corneum, epidermis, and pilosebaceous units—the exact microenvironment where inflammation and Demodex overgrowth occur. This targeted distribution ensures high local drug levels without systemic exposure.
Systemic absorption of topical ivermectin is <1%, resulting in plasma concentrations far below pharmacologically active thresholds. This eliminates systemic toxicity and differentiates ivermectin from oral antiparasitic agents.
Ivermectin’s PK profile directly supports its clinical benefits:
Metronidazole distributes more superficially and lacks follicular accumulation. Azelaic acid penetrates diffusely but is more irritating and does not target Demodex. Ivermectin’s PK profile is uniquely optimized for Demodex‑driven rosacea.
| PK factor | Effect in rosacea |
|---|---|
| Epidermal distribution | Targets follicles and inflamed epidermis |
| Systemic absorption | <1% → no systemic effects |
| Skin retention | Prolonged → sustained anti‑inflammatory action |
| Comparison to other topicals | Higher follicular targeting than metronidazole/azelaic acid |
The pharmacokinetics of topical ivermectin are uniquely suited for treating Demodex infestation. Its lipophilicity, follicular penetration, and prolonged epidermal retention create ideal conditions for sustained acaricidal activity. A detailed clinical overview is available at Ivermectin for demodex.
Demodex mites reside deep within sebaceous follicles. Ivermectin’s high lipophilicity enables it to:
Ivermectin remains in lipid‑dense compartments for extended periods. This prolonged retention ensures:
The PK profile directly supports ivermectin’s acaricidal mechanism:
| PK factor | Impact on Demodex |
|---|---|
| Follicular penetration | Reaches mites in sebaceous follicles |
| Lipid retention | Prolonged exposure → sustained killing |
| Systemic absorption | Negligible → no systemic effects |
| Clinical relevance | Strong efficacy in Demodex‑associated rosacea |
The drug–drug interaction profile of ivermectin is primarily determined by its hepatic metabolism via CYP3A4 and its high degree of plasma protein binding. These interactions are clinically relevant for oral ivermectin, where systemic concentrations are high enough for metabolic competition. In contrast, topical ivermectin produces negligible systemic exposure, making PK‑based interactions essentially irrelevant. A detailed overview of systemic interactions is available at Ivermectin oral interactions.
Oral ivermectin is metabolized mainly by CYP3A4. Drugs that inhibit or induce this enzyme can alter ivermectin plasma levels:
Strong inhibitors may increase the risk of systemic side effects when ivermectin is taken orally. Inducers may reduce antiparasitic efficacy by accelerating metabolism.
Topical ivermectin has <1% systemic absorption, meaning plasma concentrations are too low for CYP3A4‑mediated interactions. As a result, topical ivermectin is considered interaction‑neutral and safe for use alongside other dermatologic or systemic medications.
| Interaction factor | Relevance |
|---|---|
| CYP3A4 metabolism | High relevance for oral; none for topical |
| CYP3A4 inhibitors | Increase oral ivermectin levels |
| CYP3A4 inducers | Decrease oral ivermectin levels |
| Topical interactions | None — negligible systemic absorption |
The pharmacokinetic profile of ivermectin differs substantially from other topical agents used in rosacea and parasitic dermatoses. Its combination of high lipophilicity, follicular penetration, and minimal systemic absorption creates a PK pattern optimized for Demodex‑associated disease. Below is a structured comparison with metronidazole, azelaic acid, permethrin, and benzyl benzoate. Detailed comparisons are available at: Ivermectin vs Metronidazole, Ivermectin vs Azelaic acid, Ivermectin vs Permethrin, Ivermectin vs Benzyl benzoate.
Ivermectin penetrates deeply into follicles and remains in lipid‑rich structures for extended periods. Metronidazole distributes more superficially and does not accumulate in follicles, limiting its anti‑Demodex potential.
Azelaic acid penetrates diffusely but is rapidly cleared and does not concentrate in follicles. It lacks ivermectin’s lipophilic retention and does not target mites.
Permethrin penetrates the stratum corneum but is less lipophilic and more irritating. It does not achieve the same follicular concentrations as ivermectin.
Benzyl benzoate evaporates quickly, has poor retention, and causes significant irritation. Its PK profile is unsuitable for facial rosacea.
| Treatment | Absorption | Distribution | Retention | Follicular penetration |
|---|---|---|---|---|
| Ivermectin | Minimal | Epidermis + follicles | Prolonged | Strong |
| Metronidazole | Minimal | Superficial epidermis | Moderate | Weak |
| Azelaic acid | Moderate | Diffuse epidermal | Short | Weak |
| Permethrin | Low–moderate | Stratum corneum | Short | Moderate |
| Benzyl benzoate | Low | Superficial | Very short | Weak |
The pharmacokinetic profile of topical ivermectin—characterized by minimal systemic absorption, strong epidermal retention, and high lipophilicity—directly determines its clinical behavior in rosacea and Demodex‑associated dermatoses. These PK features translate into predictable therapeutic outcomes, excellent tolerability, and a favorable long‑term safety profile.
Because systemic absorption remains <1%, topical ivermectin does not reach pharmacologically active plasma concentrations. This eliminates the risk of systemic neurotoxicity, drug–drug interactions, or CNS penetration. The result is a highly safe topical therapy suitable for sensitive and reactive skin types.
Ivermectin’s lipophilicity allows it to accumulate in sebaceous follicles and remain in the epidermis for extended periods. This prolonged retention supports:
These PK‑driven effects explain why ivermectin often produces faster and more durable improvement than other rosacea topicals.
Unlike oral ivermectin, topical formulations do not rely on systemic distribution. The negligible plasma exposure ensures:
Ivermectin’s consistent epidermal distribution and minimal systemic variability create a predictable therapeutic profile. This reliability is crucial for chronic conditions like rosacea, where long‑term stability and tolerability are essential.
| Clinical effect | PK basis |
|---|---|
| High safety | Minimal systemic absorption |
| Sustained rosacea control | Prolonged epidermal retention |
| Low systemic reaction risk | No clinically relevant plasma levels |
| Predictable response | Stable distribution + consistent local concentration |